Exploration of Targeted Anti-tumor Therapy’s Post

Analysis of CDK12 alteration, in the context of MHC expression levels and LOH status, may offer improved predictive value for outcomes in this potentially actionable genomic subgroup of prostate cancer. A new paper by Jeremy Squire and team in #molecularcytogenetics #prostatecancer #cancerbiomarkers https://lnkd.in/eC2cei2S

So excited to share with you our most recently published review article titled: “ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer” In this review, we introduce the concept of liquid biopsies in the form of circulating tumor DNA (ctDNA) and the uses it has for managing non-small cell lung cancer driven by mutations in the EGFR gene, which represents 15% of all lung adenocarcinomas. If you want to learn more about ctDNA potential in early and advanced stage disease, from diagnosing to treatment, click here: https://lnkd.in/eM3Esgiz

Researchers at MD Anderson Cancer Center published a study in Nature Magazine demonstrating the potential clinical benefits of dual immune checkpoint blockade (#dualICB) in specific refractory lung cancer patients. The study indicates that a key mechanism underlying this therapeutic efficacy is the remodeling of the tumor immune microenvironment (TIME) facilitated by dual ICB. Notably, dual ICB was found to significantly modify the immune microenvironment of tumors harboring STK11 and KEAP1 mutations, leading to an increase in CD4+ T cell subsets, including TH1 T cells and effector memory CD4+ T cells, as well as inducing antigen-presenting cells that express iNOS. #cancerimmunotherapy #NSCLC #bispecific https://lnkd.in/gG75vz2u

[ #cancer #resistance ] There are currently amazing progresses in cancer tratments. Unfortunately, drug adaptation can occur. Here the authors describe a progessive cell-state transition along what they call a "resistance continum". Assembly of #gene modules expression accompanies drug adaptation. Interestingly, adapted states are associated with copy nomber alterations (CNA) and chromatin reprogramming during drug adaptation. Usinf CRISPR-based negative-selection screen, the authors reveal systems-level metabolic dependencies. The authors conclude : "Given the possibility of pharmacological control over cell-state transitions, it might be possible to either impede the adaptive process, or steer the evolving populations toward more treatable fates". #oncology https://lnkd.in/dskeKb87

Guidelines from NCCN and ASCO support NGS testing to inform treatment decisions and provide personalized treatment for cancer patients.1-3 Comprehensive testing with RNA-based NGS is recommended to capture what DNA-based NGS alone can miss.4,5 www.FindTheFusions.com #FindTheFusions 

Congratulations to SimBioSys, Inc. scientists Jesse Bucksot, PhD, Katherine Ritchie, John C. and Daniel Cook for their new work defining metabolic hallmarks across 34 cancer types identified in 10,915 patients! The method, published in Cancers, provides biological interpretability to metabolic biomarkers answering questions such as: • How does the growth rate of this tumor compare to those from other patients with the same cancer type? • What metabolic pathways deviate from expected values based on a large cohort of patients? • Are those pathways druggable? Read more here ► https://lnkd.in/gGibTiZ8 #CancerResearch #HallmarksOfCancer #MetabolicModeling #PrecisionMedicine

#mRNA for breast cancer treatment. In this paper, PTPN14 is identified as a key factor in dephosphorylating breast cancer antiestrogen resistance 3, a novel substrate, leading to the subsequent inhibition of PI3K/AKT and ERK signaling pathways. Local delivery of PTPN14 #mRNA/LNP in a TNBC mouse model has effectively inhibited tumor growth and metastasis, prolonging survival. 

More and more tissue-agnostic therapeutic options are being approved by the FDA for clinical use. The therapies target various genomic alterations, and their combinations that lead to cancer progression. Currently, those alterations are best detected by large NGS panels, also called “molecular microscope”. In this paper authors list currently available target/drug combinations (based on mutations, fusions/rearrangements, and microsatellite instability), illustrate emerging tissue-agnostic targets, and invite to expand search for agnostic therapeutics for all cancer types, beyond DNA-based biomarkers #cancermanagment #tissueagnostic

A research team from Guilin Medical University collected RNA-sequencing (RNA-seq) data of COAD from The Cancer Genome Atlas (TCGA) and Gene Expression Ominibus (GEO) databases. They calculated the immune infiltration scores of every sample using CIBERSORT algorithm. Through weighted gene co-expression network analysis (WGCNA) and picked out M2 macrophage-related genes. With these genes screened out prognosis related genes which were utilized to construct a signature to assess the prognosis of patients. To extend the potential application of the signature, they also calculated the correlations with immune infiltration. Finally, the techniques such as quantitative reverse transcription polymerase chain reaction (qRT–PCR) and immunoblotting (Western Blotting) to validate the RNF32 gene in cellular in vitro assays. GenCefe Biotech provided the PCDH-RNF32, RNF32 siRNA, and negative control for the research. Learn more about our siRNA synthesis services: https://lnkd.in/gRN3WmZK #GenCefe #siNRA #RNAi #RNF32

Our latest publication in Front. Oncol., Sec. Cancer Molecular Targets and Therapeutics, titled "Investigating Underlying Molecular Mechanisms, Signaling Pathways, and Emerging Therapeutic Approaches in Pancreatic Cancer," offers an in-depth analysis of the current molecular and genetic landscape of PDAC. Critical analysis of existing therapeutic strategies are highlighted with challenges such as drug resistance and the tumor microenvironment. Congratulations to all authors Mohd Mustafa Anas Shamsi gulam hasan Full paper is available to read: https://lnkd.in/gwPqwRkx #PancreaticCancer #MolecularMechanisms #SignalingPathways #TherapeuticApproaches #OncologyResearch #FrontOncology #CancerResearch #Immunotherapy #TargetedTherapies #CRISPR